Login to Your Account



Pharma: Clinic roundup


Friday, May 9, 2014
Dompe Group, of Milan, reported preliminary phase I results confirming the tolerability of its recombinant human nerve growth factor (rhNGF), in development for ophthalmic use as a treatment for neurotrophic keratitis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription